Cargando…

Axitinib in metastatic renal cell carcinoma: single center experience

AIM OF THE STUDY: Due to the emergence of new therapeutic opportunities in the second-line treatment of metastatic renal cell carcinoma, the choice of the appropriate medication requires consideration. Making the selection one should take into account the likelihood of response, the probability of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buraczewska, Agnieszka, Kardas, Joanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2017
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5320462/ https://www.ncbi.nlm.nih.gov/pubmed/28239287 http://dx.doi.org/10.5114/wo.2016.65609

Ejemplares similares

Axitinib in Metastatic Renal Cell Carcinoma
por: Mittal, Kriti, et al.
Publicado: (2012)

Axitinib for the Management of Metastatic Renal Cell Carcinoma
por: Escudier, Bernard, et al.
Publicado: (2012)

Axitinib in sequential therapy in metastatic renal cell carcinoma
por: Kuchar, Agata, et al.
Publicado: (2016)

Response to post-axitinib treatment in patients with metastatic renal cell carcinoma
por: Chittoria, Namita, et al.
Publicado: (2016)

Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan
por: Koie, Takuya, et al.
Publicado: (2015)

Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma
por: Osawa, Takahiro, et al.
Publicado: (2020)

Impaired Retinal Circulation during Axitinib Treatment for Metastatic Renal Cell Carcinoma
por: Kimura, Masashi, et al.
Publicado: (2019)

A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients
por: Schindler, E, et al.
Publicado: (2017)

Dose escalation of axitinib on disease progression as a strategy in the treatment of metastatic renal cell carcinoma
por: Doherty, Gary Joseph, et al.
Publicado: (2018)

Axitinib: Newly Approved for Renal Cell Carcinoma
por: Tyler, Timothy
Publicado: (2012)

A case of hyperammonemia occurring during treatment of metastatic renal cell carcinoma with axitinib
por: Kimura, Shoichi, et al.
Publicado: (2023)

GZ17-6.02 and axitinib interact to kill renal carcinoma cells
por: Booth, Laurence, et al.
Publicado: (2022)

ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups
por: Quinn, D.I., et al.
Publicado: (2021)

First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology
por: Numakura, Kazuyuki, et al.
Publicado: (2020)

Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
por: Ansari, Jawaher, et al.
Publicado: (2013)

Targeted treatments in advanced renal cell carcinoma: focus on axitinib
por: Verzoni, Elena, et al.
Publicado: (2014)

Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives
por: Narayan, Vivek, et al.
Publicado: (2016)

Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma
por: Zarrabi, Kevin K, et al.
Publicado: (2022)

Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)
por: Stellato, Marco, et al.
Publicado: (2023)

Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report
por: Murata, Masaki, et al.
Publicado: (2019)

Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
por: Cella, D, et al.
Publicado: (2013)

Overall survival of first‐line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study
por: Oya, Mototsugu, et al.
Publicado: (2017)

Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
por: Géczi, Lajos, et al.
Publicado: (2020)

Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy
por: Bellesoeur, Audrey, et al.
Publicado: (2017)

Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma
por: Gunnarsson, Orvar, et al.
Publicado: (2015)

Resistance to Pembrolizumab and Axitinib in Renal Cell Carcinoma: Clinical and Genomic Evaluation
por: Vlachostergios, Panagiotis J.
Publicado: (2020)

Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma
por: Zhang, Yue, et al.
Publicado: (2019)

The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma
por: Wang, Zhixin, et al.
Publicado: (2022)

A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma
por: Tiako Meyo, Manuela, et al.
Publicado: (2022)

Safety of axitinib and sorafenib monotherapy for patients with renal cell carcinoma: a meta-analysis
por: Qin, Fei, et al.
Publicado: (2018)

Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study
por: Johnson, Alison C., et al.
Publicado: (2017)

Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment
por: Grünwald, Viktor, et al.
Publicado: (2012)

Comparative efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: a systematic review and meta-analysis
por: Wang, Hai, et al.
Publicado: (2016)

Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era
por: Numakura, Kazuyuki, et al.
Publicado: (2021)

Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report
por: Katsumata, Yuki, et al.
Publicado: (2021)

Efficacy of combination therapy with pembrolizumab and axitinib for metastatic renal collecting duct cell carcinoma: A report on two cases
por: Tamada, Shinji, et al.
Publicado: (2022)

Pathological Complete Response of Metastatic Clear Cell Renal Carcinoma with Pembrolizumab and Axitinib: A Case Report and Review of Literature
por: Beirat, Amir F., et al.
Publicado: (2023)

Development and validation of a nomogram to evaluate the therapeutic effects of second-line axitinib in patients with metastatic renal cell carcinoma
por: Lin, Dengqiang, et al.
Publicado: (2023)

Interference of Herbal Medicine with Axitinib in Metastatic Renal Cell Cancer Treatment: A Case Study
por: Himmelreich, Friederike, et al.
Publicado: (2023)

Axitinib as a third or further line of treatment in renal cancer: a single institution experience
por: Tsironis, G., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1j70vola2u68d9ontb8ilpdu84